Prostate-Specific Membrane Antigen–Targeted Imaging With [18F]DCFPyL in High-Grade Gliomas


    loading  Checking for direct PDF access through Ovid

Abstract

High-grade gliomas (World Health Organization grade III–IV) are highly lethal primary brain tumors. Imaging modalities, including MRI and FDG PET, provide a limited ability to differentiate treatment effects (such as radiation necrosis) from recurrent or residual tumor. As the first step in validating the applicability of prostate-specific membrane antigen (PSMA)–targeted imaging in high-grade gliomas, we evaluated the ability of the PSMA-targeted small molecule [18F]DCFPyL (2-(3-(1carboxy-5-(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl)-ureido)-pentanedioic acid) to image high-grade gliomas in a series of 3 prospectively recruited patients. We found [18F]DCFPyL binds PSMA in the neovasculature of glioblastoma multiforme and tumor cells of anaplastic astrocytoma.

    loading  Loading Related Articles